{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:42:04Z","timestamp":1762360924753,"version":"build-2065373602"},"reference-count":155,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013870","name":"Astex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.soc.2022.03.014","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:21:15Z","timestamp":1655248875000},"page":"485-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Vascular Sarcoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Aparna","family":"Subramaniam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Giani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Frezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.soc.2022.03.014_bib1","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib2","doi-asserted-by":"crossref","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib3","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1378\/chest.11-0039","article-title":"Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer","volume":"140","author":"Lau","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41379-019-0368-8","article-title":"Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets","volume":"33","author":"Rosenbaum","year":"2020","journal-title":"Mod Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2022.03.014_bib5","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1038\/modpathol.2013.176","article-title":"Malignant vascular tumors--an update","volume":"27","author":"Antonescu","year":"2014","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib6","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.esmoop.2021.100170","article-title":"Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","volume":"6","author":"Stacchiotti","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1186\/s12885-018-4934-0","article-title":"Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study","volume":"18","author":"Shiba","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib8","doi-asserted-by":"crossref","first-page":"100083","DOI":"10.1016\/j.esmoop.2021.100083","article-title":"Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network","volume":"6","author":"Frezza","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/modpathol.3800065","article-title":"Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody","volume":"17","author":"Rossi","year":"2004","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.soc.2022.03.014_bib10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000001487","article-title":"Primary vascular tumors of bone: a monoinstitutional morphologic and molecular analysis of 427 cases with emphasis on epithelioid variants","volume":"44","author":"Righi","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.soc.2022.03.014_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.20886","article-title":"A\u00a0novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites","volume":"50","author":"Errani","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.soc.2022.03.014_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/gcc.22839","article-title":"Variant WWTR1 gene fusions in epithelioid hemangioendothelioma-a genetic subset associated with cardiac involvement","volume":"59","author":"Suurmeijer","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1183\/09031936.98.12010089","article-title":"Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression","volume":"12","author":"Kitaichi","year":"1998","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(06)70697-0","article-title":"Spontaneous complete regression of hepatic epithelioid haemangioendothelioma","volume":"7","author":"Otrock","year":"2006","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/PAS.0000000000001660","article-title":"Clinicopathologic characterization of epithelioid hemangioendothelioma in a series of 62 cases: a proposal of risk stratification and identification of a synaptophysin-positive aggressive subset","volume":"45","author":"Shibayama","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.soc.2022.03.014_bib16","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.athoracsur.2006.06.068","article-title":"Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature","volume":"82","author":"Bagan","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.soc.2022.03.014_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clinimag.2019.06.002","article-title":"Imaging findings in epithelioid hemangioendothelioma","volume":"58","author":"Epelboym","year":"2019","journal-title":"Clin Imaging"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib18","first-page":"259","article-title":"Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor","volume":"8","author":"Sardaro","year":"2014","journal-title":"Oncol Rev"},{"issue":"9","key":"10.1016\/j.soc.2022.03.014_bib19","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.21873\/anticanres.13675","article-title":"The role of local therapy in multi-focal epithelioid haemangioendothelioma","volume":"39","author":"Tong","year":"2019","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib20","first-page":"473","article-title":"Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience","volume":"35","author":"Yousaf","year":"2015","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.soc.2022.03.014_bib21","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cam4.3807","article-title":"Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature","volume":"10","author":"Frezza","year":"2021","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.soc.2022.03.014_bib22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(05)70392-2","article-title":"Response of epithelioid haemangioendothelioma to liposomal doxorubicin","volume":"6","author":"Kelly","year":"2005","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.soc.2022.03.014_bib23","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1200\/JCO.2011.35.5891","article-title":"Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin","volume":"29","author":"Grenader","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.soc.2022.03.014_bib25","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/cncr.28109","article-title":"Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF\/GETO)","volume":"119","author":"Chevreau","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2022.03.014_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12885-015-1395-6","article-title":"Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options","volume":"15","author":"Semenisty","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Kollar","year":"2017","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.soc.2022.03.014_bib28","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1245\/s10434-016-5331-z","article-title":"Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian Rare Cancer Network database","volume":"23","author":"Stacchiotti","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2022.03.014_bib29","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1200\/JCO.2021.39.15_suppl.11503","article-title":"P10015\/SARC033: a phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE)","volume":"39","author":"Schuetze","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up\u2217","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2022.03.014_bib31","article-title":"Team-based outpatient early palliative care: a complex cancer intervention","author":"Zimmermann","year":"2019","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpeds.2012.06.044","article-title":"Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals","volume":"162","author":"Croteau","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib33","first-page":"457","article-title":"Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon","volume":"179","author":"Ji","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib34","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/archpedi.1940.01990160135009","article-title":"Capillary hemangioma with extensive purpura: report of a case","volume":"59","author":"Kasabach","year":"1940","journal-title":"Am J Dis Child"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00000478-200405000-00001","article-title":"Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma","volume":"28","author":"Lyons","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpeds.2013.03.080","article-title":"Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma","volume":"163","author":"Drolet","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib37","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.30775","article-title":"Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study","volume":"141","author":"Ji","year":"2017","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/PAS.0b013e3181ff0901","article-title":"Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior","volume":"35","author":"Hornick","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cancergen.2011.01.002","article-title":"Translocation t(7;19)(q22;q13)-a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?","volume":"204","author":"Trombetta","year":"2011","journal-title":"Cancer Genet"},{"issue":"12","key":"10.1016\/j.soc.2022.03.014_bib40","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000001147","article-title":"Expanding the spectrum of genetic alterations in pseudomyogenic hemangioendothelioma with recurrent novel ACTB-FOSB gene fusions","volume":"42","author":"Agaram","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/gcc.22891","article-title":"A\u00a0novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone","volume":"60","author":"Bridge","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/his.14349","article-title":"Novel EGFL7-FOSB fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease","volume":"79","author":"Hakar","year":"2021","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/ccr3.3808","article-title":"Pseudomyogenic hemangioendothelioma of bone with rare WWTR1-FOSB fusion gene: case report and literature review","volume":"9","author":"Murshed","year":"2021","journal-title":"Clin Case Rep"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13000-016-0530-2","article-title":"Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics","volume":"11","author":"Sugita","year":"2016","journal-title":"Diagn Pathol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/PAS.0000000000000795","article-title":"FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma","volume":"41","author":"Hung","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.soc.2022.03.014_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13569-015-0037-8","article-title":"Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma","volume":"5","author":"Joseph","year":"2015","journal-title":"Clin Sarcoma Res"},{"issue":"6","key":"10.1016\/j.soc.2022.03.014_bib47","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/MPH.0000000000000778","article-title":"Everolimus for treatment of pseudomyogenic hemangioendothelioma","volume":"39","author":"Ozeki","year":"2017","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib48","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-17-3512","article-title":"Telatinib is an effective targeted therapy for pseudomyogenic hemangioendothelioma","volume":"24","author":"van","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00000478-199402000-00001","article-title":"Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases","volume":"18","author":"Calonje","year":"1994","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib50","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.12835","article-title":"Vascular tumours in infants. Part II: vascular tumours of intermediate malignancy [corrected] and malignant tumours","volume":"171","author":"Colmenero","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.soc.2022.03.014_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/756246","article-title":"Unresectable retiform hemangioendothelioma treated with external beam radiation therapy and chemotherapy: a case report and review of the literature","volume":"2010","author":"Hirsh","year":"2010","journal-title":"Sarcoma"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00000478-200003000-00003","article-title":"Composite hemangioendothelioma: a complex, low-grade vascular lesion mimicking angiosarcoma","volume":"24","author":"Nayler","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib53","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/PAP.0000000000000079","article-title":"Composite hemangioendothelioma: clinical and histologic features of an enigmatic entity","volume":"22","author":"Shang Leen","year":"2015","journal-title":"Adv Anat Pathol"},{"issue":"10","key":"10.1016\/j.soc.2022.03.014_bib54","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/modpathol.2017.116","article-title":"Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant","volume":"30","author":"Perry","year":"2017","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.soc.2022.03.014_bib55","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1097\/PAS.0000000000001575","article-title":"Recurrent YAP1 and MAML2 gene rearrangements in retiform and composite hemangioendothelioma","volume":"44","author":"Antonescu","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib56","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.2017.74.9812","article-title":"Pathologic angiogenesis of malignant vascular sarcomas: implications for treatment","volume":"36","author":"Khan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000225008","article-title":"Cellular injury and cell proliferation in skin carcinogenesis by UV light","volume":"31","author":"Stenback","year":"1975","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/1097-0142(20010701)92:1<172::AID-CNCR1306>3.0.CO;2-K","article-title":"Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma","volume":"92","author":"Huang","year":"2001","journal-title":"Cancer"},{"issue":"3 Suppl 1","key":"10.1016\/j.soc.2022.03.014_bib60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1590\/abd1806-4841.20153685","article-title":"Stewart Treves syndrome","volume":"90","author":"Pereira","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.1974.03240010032024","article-title":"Liver damage and angiosarcoma in vinyl chloride workers. A systematic detection program","volume":"230","author":"Makk","year":"1974","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.soc.2022.03.014_bib62","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1289\/ehp.02110s5883","article-title":"Pathology related to chronic arsenic exposure","volume":"110","author":"Centeno","year":"2002","journal-title":"Environ Health Perspect"},{"issue":"8154","key":"10.1016\/j.soc.2022.03.014_bib63","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(79)92373-0","article-title":"Hepatic angiosarcoma associated with androgenic-anabolic steroids","volume":"2","author":"Daneshmend","year":"1979","journal-title":"Lancet"},{"issue":"3\u20134","key":"10.1016\/j.soc.2022.03.014_bib64","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13577140500353743","article-title":"Angiosarcoma with malignant peripheral nerve sheath tumour developing in a patient with Klippel-Trenaunay-Weber syndrome","volume":"9","author":"Ploegmakers","year":"2005","journal-title":"Sarcoma"},{"key":"10.1016\/j.soc.2022.03.014_bib65","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.1038\/ncomms9383","article-title":"A\u00a0mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families","volume":"6","author":"Calvete","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib66","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jclinpath-2017-204601","article-title":"Cutaneous angiosarcoma: a current update","volume":"70","author":"Shustef","year":"2017","journal-title":"J\u00a0Clin Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11912-013-0328-2","article-title":"Vascular sarcomas","volume":"15","author":"Ravi","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.soc.2022.03.014_bib68","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cll.2017.06.004","article-title":"Cutaneous malignant vascular neoplasms","volume":"37","author":"Shon","year":"2017","journal-title":"Clin Lab Med"},{"issue":"18","key":"10.1016\/j.soc.2022.03.014_bib70","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1002\/cncr.24462","article-title":"Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival","volume":"115","author":"Mery","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.soc.2022.03.014_bib71","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ejso.2015.04.022","article-title":"Primary hepatic angiosarcoma","volume":"41","author":"Chaudhary","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.03.014_bib72","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1245\/s10434-012-2334-2","article-title":"Cardiac angiosarcoma management and outcomes: 20-year single-institution experience","volume":"19","author":"Look Hong","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib73","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1159\/000493656","article-title":"Clinical characteristics and prognostic factors of primary splenic angiosarcoma: a retrospective clinical analysis from China","volume":"49","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"10.1016\/j.soc.2022.03.014_bib74","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/00000478-199806000-00005","article-title":"Angiosarcoma of soft tissue: a study of 80 cases","volume":"22","author":"Meis-Kindblom","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2559.2011.03750.x","article-title":"Distinct histological features characterize primary angiosarcoma of bone","volume":"58","author":"Verbeke","year":"2011","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib76","first-page":"82","article-title":"Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor","volume":"7","author":"Miettinen","year":"1994","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jclinpath-2014-202629","article-title":"The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases","volume":"68","author":"Sullivan","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib78","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ng.2921","article-title":"Recurrent PTPRB and PLCG1 mutations in angiosarcoma","volume":"46","author":"Behjati","year":"2014","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.soc.2022.03.014_bib79","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1002\/cncr.27614","article-title":"Alterations of the p53 and PIK3CA\/AKT\/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.soc.2022.03.014_bib80","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<952::AID-IJC7>3.0.CO;2-X","article-title":"Mutations of p53 tumor-suppressor gene in angiosarcoma","volume":"71","author":"Naka","year":"1997","journal-title":"Int J Cancer"},{"issue":"34","key":"10.1016\/j.soc.2022.03.014_bib81","doi-asserted-by":"crossref","first-page":"36041","DOI":"10.18632\/oncotarget.5936","article-title":"Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway","volume":"6","author":"Murali","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/PAS.0000000000000582","article-title":"Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations","volume":"40","author":"Huang","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0560.2011.01843.x","article-title":"FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations","volume":"39","author":"Fernandez","year":"2012","journal-title":"J\u00a0Cutan Pathol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2353\/ajpath.2010.090637","article-title":"MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema","volume":"176","author":"Manner","year":"2010","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/modpathol.2011.134","volume":"25","author":"Mentzel","year":"2012","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib86","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/modpathol.2013.163","article-title":"MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study","volume":"27","author":"Shon","year":"2014","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib87","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/DAD.0000000000001053","article-title":"Immunohistochemical and fluorescence in\u00a0situ hybridization analysis of MYC in a series of 17 cutaneous angiosarcomas: a single-center study","volume":"40","author":"Requena","year":"2018","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib88","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/j.ijrobp.2021.07.972","article-title":"High terminal hemorrhage risk from cardiac angiosarcoma brain metastases warrants frequent brain imaging and early intervention","volume":"111","author":"Bishop","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib89","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z","article-title":"Angiosarcoma. A report of 67 patients and a review of the literature","volume":"77","author":"Mark","year":"1996","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113321","article-title":"Optimal clinical management and the molecular biology of angiosarcomas","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.soc.2022.03.014_bib92","doi-asserted-by":"crossref","first-page":"11517","DOI":"10.1200\/JCO.2020.38.15_suppl.11517","article-title":"A\u00a0phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma","volume":"38","author":"Ravi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib93","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hed.21513","article-title":"Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp","volume":"33","author":"Guadagnolo","year":"2011","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.soc.2022.03.014_bib94","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/cncr.11667","article-title":"Cutaneous angiosarcoma of the scalp: a multidisciplinary approach","volume":"98","author":"Pawlik","year":"2003","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.soc.2022.03.014_bib95","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials","volume":"50","author":"Young","year":"2014","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.soc.2022.03.014_bib96","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib97","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00130404-200505000-00011","article-title":"A\u00a014-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy","volume":"11","author":"Fury","year":"2005","journal-title":"Cancer J"},{"issue":"32","key":"10.1016\/j.soc.2022.03.014_bib98","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.soc.2022.03.014_bib99","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial","volume":"33","author":"Ray-Coquard","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib101","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF\/GETO)","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.soc.2022.03.014_bib102","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2022.03.014_bib103","doi-asserted-by":"crossref","first-page":"v683","DOI":"10.1093\/annonc\/mdz283","article-title":"Results of the TAPPAS trial: an adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)","volume":"30","author":"Jones","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2022.03.014_bib104","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2019.07.024","article-title":"Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours","volume":"120","author":"Jones","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.soc.2022.03.014_bib105","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib106","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anndiagpath.2010.07.012","article-title":"Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007","volume":"15","author":"Albores-Saavedra","year":"2011","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib108","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/hed.24554","article-title":"Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: systematic review and meta-analysis","volume":"39","author":"Shin","year":"2017","journal-title":"Head Neck"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111780","article-title":"Prognostic factors in a large\u00a0nationwide cohort of histologically confirmed primary and secondary angiosarcomas","volume":"11","author":"Weidema","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.soc.2022.03.014_bib110","doi-asserted-by":"crossref","DOI":"10.1177\/2036361318771771","article-title":"A\u00a0multicenter phase II study of Q3\u00a0week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma","volume":"10","author":"Bui","year":"2018","journal-title":"Rare Tumors"},{"issue":"10","key":"10.1016\/j.soc.2022.03.014_bib111","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P","article-title":"Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face","volume":"86","author":"Fata","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2022.03.014_bib112","doi-asserted-by":"crossref","first-page":"6862090","DOI":"10.1155\/2016\/6862090","article-title":"Confirmed activity and tolerability of weekly paclitaxel in the treatment of advanced angiosarcoma","volume":"2016","author":"Apice","year":"2016","journal-title":"Sarcoma"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib113","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.22822","article-title":"Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients","volume":"110","author":"Nagano","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2022.03.014_bib114","doi-asserted-by":"crossref","first-page":"532478","DOI":"10.1155\/2015\/532478","article-title":"Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma","volume":"2015","author":"Dickson","year":"2015","journal-title":"Sarcoma"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000492597","article-title":"Differences in the efficacies of pazopanib and gemcitabine\/docetaxel as second-line treatments for metastatic soft tissue sarcoma","volume":"96","author":"Kim","year":"2019","journal-title":"Oncology"},{"issue":"15_suppl","key":"10.1016\/j.soc.2022.03.014_bib116","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1200\/JCO.2019.37.15_suppl.11039","article-title":"Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS)","volume":"37","author":"Mehren","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib117","first-page":"265","article-title":"Kaposi. Idiopathisches multiples Pigmentsarkom der Haut","volume":"4","year":"1872","journal-title":"Archiv f\u00fcr Dermatologie und Syphilis"},{"issue":"5192","key":"10.1016\/j.soc.2022.03.014_bib118","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"issue":"6693","key":"10.1016\/j.soc.2022.03.014_bib119","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/29093","article-title":"Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus","volume":"394","author":"Flore","year":"1998","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib121","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<500::AID-CNCR3>3.0.CO;2-9","article-title":"Classic Kaposi sarcoma: epidemiology and risk factors","volume":"88","author":"Iscovich","year":"2000","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib122","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/bjc.1998.717","article-title":"The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic","volume":"78","author":"Cook-Mozaffari","year":"1998","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.soc.2022.03.014_bib123","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(08)70175-X","article-title":"Part I: cancer in indigenous Africans--burden, distribution, and trends","volume":"9","author":"Parkin","year":"2008","journal-title":"Lancet Oncol"},{"issue":"8682","key":"10.1016\/j.soc.2022.03.014_bib124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0140-6736(90)90001-L","article-title":"Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?","volume":"335","author":"Beral","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1017\/S0950268812000325","article-title":"Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005","volume":"141","author":"Armstrong","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.soc.2022.03.014_bib126","first-page":"18","article-title":"Kaposi's sarcoma and transplantation","volume":"7","author":"Mendez","year":"2000","journal-title":"Herpes"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib127","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.seminoncol.2014.12.029","article-title":"The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation","volume":"42","author":"Grulich","year":"2015","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.03.014_bib128","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jdv.14831","article-title":"A\u00a0fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris","volume":"32","author":"Denis","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/QAI.0000000000000862","article-title":"Accuracy of clinical suspicion and pathologic diagnosis of Kaposi sarcoma in East Africa","volume":"71","author":"Amerson","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2019.03.028","article-title":"Management of Kaposi sarcoma after solid organ transplantation: a European retrospective study","volume":"81","author":"Delyon","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.soc.2022.03.014_bib131","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/QAD.0b013e328360a5a1","article-title":"Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK","volume":"27","author":"Letang","year":"2013","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib132","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","article-title":"Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma","volume":"32","author":"Bower","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2022.03.014_bib133","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","article-title":"Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF\/EADO\/EORTC)","volume":"114","author":"Lebbe","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.soc.2022.03.014_bib134","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib135","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group","volume":"16","author":"Stewart","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.03.014_bib136","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.soc.2022.03.014_bib137","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1002\/cncr.25362","article-title":"Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy","volume":"116","author":"Cianfrocca","year":"2010","journal-title":"Cancer"},{"issue":"10231","key":"10.1016\/j.soc.2022.03.014_bib138","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(19)33222-2","article-title":"Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial","volume":"395","author":"Krown","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.soc.2022.03.014_bib139","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2011.39.6853","article-title":"Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy","volume":"30","author":"Uldrick","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.soc.2022.03.014_bib140","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi's sarcoma in people with and without hiv infection: a phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.014_bib141","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2012.48.6365","article-title":"Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042","volume":"32","author":"Koon","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.soc.2022.03.014_bib142","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.2002.12.038","article-title":"Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study","volume":"20","author":"Evans","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib143","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1078-0432.CCR-19-1044","article-title":"Pilot Trial AMC-063: safety and efficacy of bortezomib in AIDS-associated Kaposi sarcoma","volume":"26","author":"Reid","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2022.03.014_bib144","doi-asserted-by":"crossref","first-page":"102266","DOI":"10.1016\/j.ctrv.2021.102266","article-title":"Emerging therapies for rare cutaneous cancers: a systematic review","volume":"100","author":"Garcia","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.soc.2022.03.014_bib145","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.soc.2022.03.014_bib146","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdy006","article-title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","volume":"29","author":"Delyon","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.soc.2022.03.014_bib147","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soc.2022.03.014_bib148","doi-asserted-by":"crossref","first-page":"S732","DOI":"10.1016\/j.annonc.2020.08.1201","article-title":"PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: a multicenter phase II study","volume":"31","author":"Delyon","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib149","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/bjc.1996.635","article-title":"Survival of classic Kaposi's sarcoma and risk of second cancer","volume":"74","author":"Franceschi","year":"1996","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112519","article-title":"Systemic treatment initiation in classical and endemic Kaposi's sarcoma: risk factors and global multi-state modelling in a monocentric cohort study","volume":"13","author":"Benajiba","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.soc.2022.03.014_bib151","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1997.15.9.3085","article-title":"AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee","volume":"15","author":"Krown","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.soc.2022.03.014_bib152","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2003.10.162","volume":"21","author":"Nasti","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2022.03.014_bib153","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jnci\/djq134","article-title":"Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion","volume":"102","author":"Lodi","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.soc.2022.03.014_bib154","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11255-008-9483-z","article-title":"Kaposi's sarcoma following living donor kidney transplantation: review of 7,939 recipients","volume":"41","author":"Einollahi","year":"2009","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.014_bib155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ijc.31782","article-title":"Survival after the diagnosis of de novo malignancy in liver transplant recipients","volume":"144","author":"Taborelli","year":"2019","journal-title":"Int J Cancer"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:38:37Z","timestamp":1762360717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1055320722000278"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.03.014","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Vascular Sarcoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}